<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962934</url>
  </required_header>
  <id_info>
    <org_study_id>Royal_Brisbane</org_study_id>
    <nct_id>NCT02962934</nct_id>
  </id_info>
  <brief_title>An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without CRRT</brief_title>
  <acronym>CT-PK</acronym>
  <official_title>An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without Continuous Renal Replacement Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brisbane and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Brisbane and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to try to find out how critically ill patients receiving the&#xD;
      antibiotic, ceftolozane-tazobactam, process it in their body. Investigators would like to&#xD;
      study if the antibiotic concentrations during a dose of this antibiotic reaches the right&#xD;
      concentrations necessary to kill the bacteria that is causing the infection. The process by&#xD;
      which a drug travels through the body in blood, how it is broken down and removed by the body&#xD;
      is called pharmacokinetics (PK). We can measure the PK by taking blood samples at specific&#xD;
      times after the antibiotic is given.&#xD;
&#xD;
      Investigators would like to do the study in patients receiving dialysis and patients who are&#xD;
      not receiving dialysis. This information about how the antibiotic is processed in the&#xD;
      critically ill patient is unknown and it is important to know whether the doses doctors give&#xD;
      patients to fight infection are adequate. If antibiotic concentrations are low in the blood,&#xD;
      it gives the bacteria an opportunity to become resistant to the antibiotic which can lead to&#xD;
      the antibiotic being less effective against bacteria potentially exposing future patients&#xD;
      with infections to a limited range of effective antibiotics.&#xD;
&#xD;
      Patients will be consented, and given the antibiotic as prescribed. Blood samples will be&#xD;
      taken from the drip that is already in the patients arm just as the antibiotic starts, at 15&#xD;
      and 45 minutes, at 1,2,3,4,5,6,7 and 8 hours. Patients who are on dialysis will have the&#xD;
      blood samples taken from the dialysis machine before the blood reaches the dialysis filter&#xD;
      (same blood samples as the non dialysis patients) and also bloods samples taken after the&#xD;
      filter at 45 minutes, 2 and 6 hours. Dialysis patients will also have 5 separate samples of&#xD;
      ultrafiltrate taken (approximately 10mls) - ultrafiltrate is the waste product of the&#xD;
      dialysis process. The total amount of blood will be 40mls which is equal to about 2&#xD;
      tablespoons. The dialysis patient will have 50mls of blood taken.Information about the&#xD;
      patients ICU stay will also be recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ceftolozane-tazobactam has recently emerged as a highly valuable option for the management of&#xD;
      severe Gram-negative infections including those caused by multi-drug resistant (MDR)&#xD;
      organisms, demonstrating superior antibacterial activity against the pathogens most&#xD;
      frequently causing serious infection in the critically ill, such as Pseudomonas aeruginosa&#xD;
      and Enterobacteriaceae spp, when compared with other commonly used beta-lactam antibiotics.&#xD;
&#xD;
      Although the continued reduction in the pathogen susceptibility to commonly used antibiotics&#xD;
      in ICUs could be multifactorial, the potential contribution from inappropriate antibiotic&#xD;
      exposure is undoubtedly very significant. Numerous clinical studies have reported&#xD;
      sub-therapeutic antibiotic concentrations in ICU patients across different antibiotic&#xD;
      classes, with conventional dosing regimens. This is due to marked changes in the&#xD;
      pharmacokinetics (PK) and pharmacodynamics (PD) of antibiotics in the critically ill arising&#xD;
      from disease-related physiological changes. Ceftolozane being a structural analogue of&#xD;
      ceftazidime, shares similar PK properties of ceftazidime, and other beta-lactams, with a&#xD;
      short half-life of about 2 hours, distribution into extracellular fluid, and predominant&#xD;
      renal elimination, which all make it vulnerable to disease-related PK alterations in the&#xD;
      critically ill.&#xD;
&#xD;
      Inappropriate antibiotic exposure in the ICU can also arise due to use of extracorporeal&#xD;
      therapies such as continuous renal replacement therapy (CRRT). Many beta-lactam antibiotics&#xD;
      share similar physicochemical and PK properties with ceftolozane and are efficiently cleared&#xD;
      by CRRT machines. However the extent of total drug clearance during CRRT is variable not only&#xD;
      due to the different modalities and operational settings across different institutions, but&#xD;
      also due to the variable residual renal clearance associated with the degree of renal&#xD;
      impairment. The traditional dosing considerations in patients undergoing CRRT mainly focus on&#xD;
      the notion of renal impairment and generally consider low doses without giving appropriate&#xD;
      consideration to the possibly high extracorporeal clearance, and thus risking under dosing.&#xD;
      In a similar fashion, the product information for ceftolozane-tazobactam or the prescriber's&#xD;
      information by the United States Food and Drug Administration (FDA), recommends a ten-fold&#xD;
      lower-than-normal dose for use during renal replacement therapy (maintenance dose of 150mg&#xD;
      versus 1.5g in those with normal renal function). However, to date there is limited data from&#xD;
      clinical studies during CRRT in ICU patients to confirm if such a low dose provides&#xD;
      appropriate antibiotic exposure. Lessons from studies on other beta-lactams suggest that&#xD;
      ceftolozane may be subject to extensive but variable clearance during CRRT. It is therefore,&#xD;
      essential to describe the adequacy of dosing in patients receiving CRRT, given that fact and&#xD;
      that several additional pathophysiological factors affect the PK and PD of antibiotics even&#xD;
      in the absence of extracorporeal circuits.&#xD;
&#xD;
      This prospective observational study will describe, firstly, the PK of ceftolozane-tazobactam&#xD;
      in ICU patients who are not receiving CRRT, and secondly, the influence of CRRT on the PK and&#xD;
      dosing requirements of ceftolozane-tazobactam in critically ill patients. This study will&#xD;
      generate new PK data in ICU patients describing the exposure to ceftolozane-tazobactam from&#xD;
      the recommended dosing regimen thereby allowing assessment of its adequacy and/or defining&#xD;
      appropriate dosing. Further, it will provide invaluable insight into the altered dosing needs&#xD;
      of patients receiving CRRT to enable its use in such patients through prediction of any&#xD;
      necessary dosing corrections to account for the due effect of CRRT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of Target Attainment for 40% fT&gt;MIC</measure>
    <time_frame>24 hour period</time_frame>
    <description>The probability of attaining free concentrations above MIC for 40% of the time</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">18</enrollment>
  <condition>Gram-Negative Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Non CRRT group</arm_group_label>
    <description>Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRRT group</arm_group_label>
    <description>Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non CRRT group</intervention_name>
    <description>Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.</description>
    <arm_group_label>Non CRRT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CRRT group</intervention_name>
    <description>CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.&#xD;
Ultrafiltrate samples at 1 hr,2h 4h 6h 8h</description>
    <arm_group_label>CRRT group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine, blood and ultrafiltrate&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients receiving Ceftolozane-tazobactam for gram negative infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1 Non CRRT&#xD;
&#xD;
          -  Diagnosis of systemic infection known or suspected to be caused by an organism&#xD;
             susceptible to ceftolozane-tazobactam&#xD;
&#xD;
          -  Age more than 18 years&#xD;
&#xD;
          -  The treating clinician considers Ceftolozane-tazobactam to be an appropriate agent to&#xD;
             treat the infection Group 2 CRRT&#xD;
&#xD;
          -  Diagnosis of systemic infection known or suspected to be caused by an organism&#xD;
             susceptible to ceftolozane-tazobactam&#xD;
&#xD;
          -  Age more than18 years&#xD;
&#xD;
          -  Prescribed to receive CRRT&#xD;
&#xD;
          -  The treating clinician considers Ceftolozane-tazobactam to be an appropriate agent to&#xD;
             treat the infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Group 1 Non CRRT&#xD;
&#xD;
          -  Renal dysfunction that necessitates the use of renal replacement therapy&#xD;
&#xD;
          -  Known or suspected allergy to cephalosporins&#xD;
&#xD;
          -  Receipt of any Pipercillin-Tazobactam for the treatment of this current infection.&#xD;
&#xD;
          -  Pregnancy Group 2 CRRT&#xD;
&#xD;
          -  Known or suspected allergy to cephalosporins&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Receipt of any Pipercillin-Tazobactam for the treatment of this current infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason A Roberts, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brisbane and Womens Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <results_first_submitted>August 17, 2019</results_first_submitted>
  <results_first_submitted_qc>August 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2019</results_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Brisbane and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jason Roberts</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All data will be reported and analysed in a de-identified format.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02962934/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non CRRT Group</title>
          <description>Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy&#xD;
Non CRRT group: Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.</description>
        </group>
        <group group_id="P2">
          <title>CRRT Group</title>
          <description>Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy&#xD;
CRRT group: CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.&#xD;
Ultrafiltrate samples at 1 hr,2h 4h 6h 8h</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non CRRT Group</title>
          <description>Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy&#xD;
Non CRRT group: Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.</description>
        </group>
        <group group_id="B2">
          <title>CRRT Group</title>
          <description>Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy&#xD;
CRRT group: CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.&#xD;
Ultrafiltrate samples at 1 hr,2h 4h 6h 8h</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="52" upper_limit="61"/>
                    <measurement group_id="B2" value="61.5" lower_limit="58" upper_limit="65"/>
                    <measurement group_id="B3" value="58" lower_limit="51.5" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine</title>
          <units>micro-mole/litre</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="39" upper_limit="77"/>
                    <measurement group_id="B2" value="138" lower_limit="92" upper_limit="151.75"/>
                    <measurement group_id="B3" value="75" lower_limit="42.5" upper_limit="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Probability of Target Attainment for 40% fT&gt;MIC</title>
        <description>The probability of attaining free concentrations above MIC for 40% of the time</description>
        <time_frame>24 hour period</time_frame>
        <population>For a recommended dose of 1.5g every 8 hours for patients without CRRT and for a dosing regimen of 3g loading dose plus 0.75 g every 8 hours for patients with CRRT when evaluated at the EUCAST MIC breakpoint of 4mg/L for Pseudomonas aeruginosa</population>
        <group_list>
          <group group_id="O1">
            <title>Non CRRT Group</title>
            <description>Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy&#xD;
Non CRRT group: Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.</description>
          </group>
          <group group_id="O2">
            <title>CRRT Group</title>
            <description>Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy&#xD;
CRRT group: CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.&#xD;
Ultrafiltrate samples at 1 hr,2h 4h 6h 8h</description>
          </group>
        </group_list>
        <measure>
          <title>Probability of Target Attainment for 40% fT&gt;MIC</title>
          <description>The probability of attaining free concentrations above MIC for 40% of the time</description>
          <population>For a recommended dose of 1.5g every 8 hours for patients without CRRT and for a dosing regimen of 3g loading dose plus 0.75 g every 8 hours for patients with CRRT when evaluated at the EUCAST MIC breakpoint of 4mg/L for Pseudomonas aeruginosa</population>
          <units>percentage of time above MIC</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1week</time_frame>
      <desc>This study was observational pharmacokinetic study and not an outcomes study. No drug-related adverse events were observed during the study sampling period.&#xD;
&quot;0&quot; Total Number of Participants at Risk means that &quot;All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Non CRRT Group</title>
          <description>Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy&#xD;
Non CRRT group: Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.</description>
        </group>
        <group group_id="E2">
          <title>CRRT Group</title>
          <description>Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy&#xD;
CRRT group: CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.&#xD;
Ultrafiltrate samples at 1 hr,2h 4h 6h 8h</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Jason Roberts</name_or_title>
      <organization>University of Queensland Center for Clinical Research</organization>
      <phone>+61 7 334 65032</phone>
      <email>j.roberts2@uq.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

